Risk of CKD in Diabetic Patients With MAFLD - Trial NCT06304844
Access comprehensive clinical trial information for NCT06304844 through Pure Global AI's free database. This phase not specified trial is sponsored by Sohag University and is currently Not yet recruiting. The study focuses on Type 2 Diabetes. Target enrollment is 300 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Sohag University
Timeline & Enrollment
N/A
Apr 20, 2024
Feb 01, 2025
Primary Outcome
Determine the number of participant with eGFR60 ml/min/1.73 m2 or albuminuria (urinary albumin-to-creatinine ratio (ACR) ⩾3 mg/mmol) in patients with type 2 DM and MAFLD
Summary
This cross-sectional study of 300 participants investigates the risk of chronic kidney
 disease (CKD) in individuals with metabolic dysfunction-associated fatty liver disease
 (MAFLD) and type 2 diabetes. By evaluating hepatic measurements and metabolic markers, the
 study aims to identify key risk factors for CKD in this population, contributing valuable
 insights to inform targeted interventions.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06304844
Non-Device Trial